Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22400059 | 1.00 | THRB (0.35) | THRBLMNAL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL18541625 | 1.00 | THRB (0.35) | THRBLMNAL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL20804121 | 1.00 | THRB (0.35) | THRBLMNAL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL23822904 | 1.00 | THRB (0.35) | THRBLMNAL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL14280356 | 1.00 | THRB (0.35) | THRBLMNAL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL23226272 | 1.00 | THRB (0.35) | THRBLMNAL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL18541617 | 1.00 | THRB (0.35) | THRBLMNAL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL15484277 | 0.85 | THRB (0.44) | THRBLMNAL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL22641547 | 0.83 | ALDH1A1 (0.37) | THRBLMNAL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL9009380 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021060395-A1 | SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITION | 持田製薬株式会社 | 2021-04-01 | — | — | WO | disclosed |
| WO-2020242943-A1 | GPR40 AGONISTS | KALLYOPE, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
| EP-2139523-B1 | CONJUGATES OF FOLATE AND TUBULYSIN FOR TARGETED DRUG DELIVERY | ENDOCYTE INC (US) | 2014-10-22 | — | — | EP | disclosed |
| WO-2014085575-A1 | METHODS FOR TREATING CANCER USING COMBINATION THERAPIES | ENDOCYTE, INC. (US) | 2014-06-05 | — | — | WO | disclosed |
| EP-2489372-A2 | Binding ligand linked drug delivery conjugates of tubulysins | Endocyte, Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| EP-2481427-A1 | Folate-Tubulysin conjugates | Endocyte, Inc. (US) | 2012-08-01 | — | — | EP | disclosed |
| WO-2012047525-A2 | FOLATE CONJUGATES FOR TREATING INFLAMMATION OF THE EYE | ENDOCYTE, INC. (US) | 2012-04-12 | — | — | WO | disclosed |
| WO-2011079227-A1 | VITAMIN RECEPTOR DRUG DELIVERY CONJUGATES FOR TREATING INFLAMMATION | ENDOCYTE, INC. (US) | 2011-06-30 | — | — | WO | disclosed |
| WO-2009002993-A1 | CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS | ENDOCYTE, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| WO-2008112873-A2 | BINDING LIGAND LINKED DRUG DELIVERY CONJUGATES OF TUBULYSINS | ENDOCYTE, INC. (US) | 2008-09-18 | — | — | WO | disclosed |